Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
CRISPR Therapeutics AG's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was -10.47%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for CRISPR Therapeutics AG's 3-Year ROIIC % or its related term are showing as below:
LTS:0VRQ's 3-Year ROIIC % is ranked worse than 53.18% of 1322
companies
in the Biotechnology industry
Industry Median: -4.82
vs LTS:0VRQ: -10.47
CRISPR Therapeutics AG (LTS:0VRQ) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
CRISPR Therapeutics AG 3-Year ROIIC % Related Terms
CRISPR Therapeutics AG 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for CRISPR Therapeutics AG's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0VRQ vs ORKA, TVTX, MANE: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, CRISPR Therapeutics AG's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CRISPR Therapeutics AG 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CRISPR Therapeutics AG's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where CRISPR Therapeutics AG's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
CRISPR Therapeutics AG (LTS:0VRQ) has a 3-Year ROIIC % of -10.47 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on CRISPR Therapeutics AG and its competitors. According to the industry distribution chart, CRISPR Therapeutics AG ranks #703 out of 1322 companies in the Biotechnology industry, placing it in the top 53.2%.
Is CRISPR Therapeutics AG's 3-Year ROIIC % too high?
CRISPR Therapeutics AG's current 3-Year ROIIC % is -10.47. Based on the distribution chart, CRISPR Therapeutics AG ranks #703 out of 1322 companies in the Biotechnology industry, which is below the industry midpoint. Overall, CRISPR Therapeutics AG has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CRISPR Therapeutics AG's 3-Year ROIIC % compare to ORKA and TVTX?
According to the Biotechnology industry distribution chart, CRISPR Therapeutics AG ranks #703 out of 1322 companies for 3-Year ROIIC %. This places CRISPR Therapeutics AG in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on CRISPR Therapeutics AG and its competitors. CRISPR Therapeutics AG's current 3-Year ROIIC % is -10.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CRISPR Therapeutics AG stock overvalued right now?
Based on GuruFocus' analysis, CRISPR Therapeutics AG (LTS:0VRQ) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.59, compared to a current price of $50.69 — trading 1312% above its estimated fair value. The current 3-Year ROIIC % is -10.47. CRISPR Therapeutics AG's overall GF Score™ is 45/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For CRISPR Therapeutics AG (LTS:0VRQ), the current 3-Year ROIIC % is -10.47 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CRISPR Therapeutics AG (LTS:0VRQ) Overvalued in 2026?
Based on GuruFocus' analysis, CRISPR Therapeutics AG stock appears to be overvalued.
The current stock price of $50.69 is trading 1312% above its estimated GF Value™ of $3.59.
GuruFocus considers CRISPR Therapeutics AG to be Significantly Overvalued.
Key valuation signals for LTS:0VRQ:
3-Year ROIIC %: -10.47
GF Value™: $3.59 vs. price of $50.69 (1312% above fair value)
No single metric tells the full story. See the LTS:0VRQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
45GF Score
Get the complete analysis for LTS:0VRQ
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0VRQ has been successfully added to your 
